Date: 2014-01-28
Type of information: Development agreement
Compound: monoclonal antibody ESK1
Company: Eureka Therapeutics (USA) Memorial Sloan-Kettering Cancer Center (USA) Novartis (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: development
licensing
Action mechanism: ESK1 targets WT1, a protein that a protein that resides on the inside of the cell and is overexpressed in a range of leukemias and other cancers including myeloma and breast, ovarian, and colorectal cancers. ESK1 was engineered to mimic the functions of a T cell receptor, a key component of the immune system. As proteins inside the cell get broken down as part of regular cellular processes, fragments of those proteins are carried to the cell surface. When T cells recognize these fragments as abnormal, through T cell receptors, the T cell kills the diseased cell.
Disease: leukemia and other cancers
Details: * On January 28, 2014, Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center have announced that they have entered into a license agreement with Novartis for the development and commercialization of ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers. The antibody was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center. Under the terms of the agreement, Eureka Therapeutics and Memorial Sloan-Kettering grant Novartis an exclusive, world-wide license to develop ESK1 for all indications. In return, Eureka Therapeutics and Memorial Sloan-Kettering will receive an up-front payment and potential future payments upon achievement of development, regulatory and sales milestones, and annual net sales royalty payments. Novartis will fund and execute all additional development and commercialization activities.
Financial terms:
Latest news:
